AIM ImmunoTech Announces USPTO Granted Patent Covering Use Of Ampligen In Combination With Pembrolizumab For Cancer Treatment, Expiring December 20, 2039
Share
Why It Matters
AIM ImmunoTech got official permission from the US government to use their medicine Ampligen mixed with another cancer drug until 2039. This means the company has extra time to develop and sell this combination without competitors copying it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.